11 results about "Pharmacologic action" patented technology

This invention relates to the application of oridonin in the preparation of agents that improve muscle function, specifically by improving skeletal muscle dysfunction, enhancing insulin sensitivity, promoting myoblast differentiation into myotube cells, and / or increasing myoblast insulin sensitivity. Using an in vitro C2C12 myoblast model, this invention demonstrates that oridonin can promote myoblast differentiation and growth and increase C2C12 myoblast insulin sensitivity. Through an obesity-induced skeletal muscle dysfunction model, it is demonstrated that oridonin can improve skeletal muscle dysfunction and insulin resistance by increasing muscle strength, muscle endurance, muscle mass, and reducing muscle lipid accumulation. This invention provides new insights for drug research on improving skeletal muscle dysfunction and enhancing insulin sensitivity, and also enriches the pharmacological system of oridonin.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

The application discloses application of a Fructus Mume pill in preparation of a medicine for treating diabetic encephalopathy, and finds that there is a clear correlation between the Fructus Mume pill and the diabetic encephalopathy. Research results show that the Fructus Mume pill can improve the abnormal metabolic state of a diabetic model mouse, reduce learning and memory dysfunction and cognitive impairment under a diabetic state, and has a good prevention and treatment effect on the diabetic encephalopathy. The application clearly defines the pharmacological effect of the Fructus Mume pill in preventing and treating the diabetic encephalopathy and a possible action mechanism, and provides an experimental basis for TCM intervention on the diabetic encephalopathy. The application provides a new train of thought for research and development of a medicine related to the diabetic encephalopathy, and has a good application prospect.

The present invention provides diazo compounds having anti-trypanosomal activity, with less or no side-effects. The diazo compounds are structural analogue of quinapyramine and possess characteristics necessary for the targeted pharmacologic action of anti trypanosomosis, with reduced cytotoxicity. The compounds were found to have less cytotoxicity, and identical or better anti- parasitemia effect as compared to conventional quinapyramine sulfate.

The application discloses application of calyculostero in preparation of blood sugar reducing drugs, and belongs to the technical field of pharmacological action of calyculostero. Experimental results show that the calyculostero can inhibit the activity of pancreatic alpha-amylase (IC50 is 4.34+ / -1.10 ug / mL) in a dose-dependent manner, reduce postprandial blood sugar, and improve sugar tolerance, reduce fasting blood sugar, improve total cholesterol and triglyceride levels, and reduce histopathological changes of liver, pancreas and kidney in long-term intervention, and has no obvious hepatotoxicity. The calyculostero can be used alone or together with a pharmaceutically acceptable excipient to prepare a pharmaceutical composition, and is used for reducing blood sugar or treating diabetes, and the dosage form includes oral preparations, injections and the like. The application provides a new natural medicine selection for drug treatment of diabetes.

This invention discloses an orally disintegrating film formulation of BPC-157 sodium salt for treating acute alcohol poisoning and its preparation method. It relates to the field of acute alcohol poisoning treatment technology. The orally disintegrating film formulation comprises, by weight percentage: 0.1-5% BPC-157 sodium salt, 40-70% film-forming material, 5-15% plasticizer, 0.1-15% disintegrant, 0.1-15% sweetener, 0.1-10% salivary stimulant, and 1-5% other excipients. This invention prepares an orally disintegrating film formulation of BPC-157 sodium salt, utilizing its rapid dissolution characteristics and the pharmacological effects of BPC-157, providing a new option for treating acute alcohol poisoning. This formulation has advantages such as rapid onset of action, high bioavailability, and few side effects, and is expected to become an effective drug for treating acute alcohol poisoning.

This invention provides a method and system for big data analysis and processing of drug incompatibilities, relating to the field of pharmaceutical data processing technology. The method includes acquiring a drug dataset containing drug identifiers and pharmacological targets; performing topological adaptive hierarchical clustering based on multidimensional semantic mapping of targets; constructing local compatibility subgraphs at each level and extracting topological invariants as feature codes; calculating the topological similarity of adjacent level subgraphs using graph convolution operators to construct a compatibility risk propagation tensor field; conducting multi-scale risk signal propagation along the tensor field; and implementing adaptive attenuation and proportional allocation based on eigenvalue spectra to achieve cross-level risk aggregation and form a global risk assessment tensor; and outputting the drug combination incompatibility determination results through manifold dimensionality reduction projection.

The application discloses a naringin high-efficiency extraction process optimization and multi-dimensional biological activity research method based on a low eutectic solvent. Through systematic screening of 11 kinds of low eutectic solvents (Deep Eutectic Solvents, DESs) and 2 kinds of traditional organic solvents on the extraction efficiency of naringin, it is determined that the low eutectic solvent composed of tetraethyl ammonium bromide and 1,2-propanediol is the optimal solvent, the extraction process parameters are optimized through single factor experiment and response surface method, and the optimal extraction conditions of naringin are obtained. The extracted naringin is subjected to antioxidant and antibacterial activity detection, the MoGAPI method is used for life cycle assessment of the extraction process, and through network pharmacology and molecular docking technology, the potential action target, signal pathway and molecular binding mechanism of naringin in treating gastric cancer are explored. The method is high in extraction efficiency, green in environmental protection and safe in operation, and further systematically clarifies the multi-dimensional biological activity and potential pharmacological action of naringin, thereby providing reliable process and theoretical support for the green industrialized production and subsequent development and application of naringin.

The application discloses a natural medicine compound for treating Alzheimer's disease and application thereof, and the compound comprises the following components: 3-6 parts of Gastrodia elata, 3-6 parts of Polygala, 3-6 parts of Radix Notoginseng, 3-6 parts of Uncaria, 9-15 parts of Radix Rehmanniae Preparata, 9-15 parts of Radix Anemarrhenae, 6-10 parts of Fructus Schisandrae, 6-9 parts of Fried Semen Ziziphi Preparatum, 2-5 parts of Chuanxiong Rhizoma, 3-6 parts of Radix Paeoniae Alba, 9-15 parts of Radix et Rhizoma Bambusae, 1-5 parts of Carthamus, 6-10 parts of Atractylodes, 6-9 parts of Poria, 9-15 parts of Ophiophagus, 3-9 parts of Angelica, 9-15 parts of Radix et Rhizoma Ginseng, 2-5 parts of Salvia, and 2-5 parts of Radix Glycyrrhizae. The application further discloses a pharmacological action mechanism of the Tianqi granules for treating AD and application of the Tianqi granules in preventing and / or treating Alzheimer's disease. The application is a natural medicine, contains multiple active components, has scientific dosage, no side effect, and provides a new effective natural medicine compound for treating AD, and plays a significant role in benefiting a large number of patients and benefiting human health.

This application provides a Kampo (traditional Japanese herbal medicine) composition for treating childhood atopic dermatitis and a method for preparing the same, relating to the technical field of Kampo compositions. [Solution] The raw materials of the herbal medicine composition include 4-8 parts of Atractylodes lancea, 6-10 parts of Lonicera japonica, 4-8 parts of Phellodendron bark, 4-8 parts of Coix seed, 4-8 parts of Achyranthes bidentata, 2-8 parts of Sophora flavescens, 4-8 parts of Bletilla striata, 4-8 parts of Rehmannia glutinosa, 2-8 parts of Cicada rotundifolia, and 2-8 parts of Glycyrrhiza uralensis. The preparation method involves adding water to the herbal medicine and immersing it, then heating and reflux extraction, filtering, taking the filtrate, concentrating the filtrate to make a clear ointment, cooling, adding ethanol, letting it stand, taking the supernatant liquid and recovering the ethanol, then secondary concentration to obtain a herbal medicine paste, and finally granulating the herbal medicine paste. This invention combines traditional herbal medicine with modern pharmacological action to achieve the effects of clearing heat and removing dampness, strengthening the spleen and removing dampness, and dispelling wind and relieving itching. In actual application, it shows remarkable improvement and complete cure in the symptoms of childhood atopic dermatitis, with a rapid effect, a short treatment process, low side effects, and no recurrence after complete cure.

The application discloses a gemfibrozil deuterated derivative as shown in formula (I) and a preparation method and application thereof, and belongs to the field of organic and pharmaceutical synthesis. The method has simple preparation process and low cost. The gemfibrozil deuterated derivative synthesized by the method has the advantages of high purity and high deuterium substitution rate. The application also discloses application of the gemfibrozil deuterated derivative in treatment of hyperlipidemia. The gemfibrozil deuterated derivative has significantly improved pharmacological effect and significantly reduced toxic metabolites.